Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal Irinotecan + Albumin-paclitaxel for Second-line Advanced Gastric Cancer
NCT06486545Phase 1Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Aug 2024
- Primary completion
- Jul 2025
- Modality
- Lipid-based Nanoparticles, Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of irinotecan liposome injection in gastric cancer (GC), sponsored by Hunan Cancer Hospital. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
irinotecan liposome injection
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06486545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06486545.